Soonmo Peter Kang
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Immunology top 1%
- Immunotherapy and Immune Responses
Papers in
- Oncology 26
- Cancer Immunotherapy and Biomarkers 17
- Pancreatic and Hepatic Oncology Research 5
- CAR-T cell therapy research 4
- Colorectal Cancer Treatments and Studies 4
- Cancer Cells and Metastasis 3
-
- Gastric Cancer Management and Outcomes 5
- Co-authors
- Scot Ebbinghaus (6 shared papers)Muhammad Wasif Saif (5 shared papers)Mark J. Ratain (5 shared papers)Anthony Michael Joshua (2 shared papers)Leila Khoja (1 shared paper)Marcus Otho Butler (1 shared paper)Lyndsay N. Harris (5 shared papers)Kapil Mayawala (2 shared papers)
- Journals
- Annals of Oncology (8 papers)Clinical Cancer Research (6 papers)Journal for ImmunoTherapy of Cancer (5 papers)Journal of Clinical Oncology (2 papers)JAMA Oncology (2 papers)
- Partner nations
- United StatesJapanSouth Korea
In The Last Decade
Soonmo Peter Kang
44 papers receiving 13.0k citations
Soonmo Peter Kang's Hit Papers
Peers
Comparison fields: 5 of 118
- Oncology 8.1k
- Immunology 2.7k
- Cancer Research 1.6k
- Pulmonary and Respiratory Medicine 2.7k
- Pathology and Forensic Medicine 1.5k
Countries citing papers authored by Soonmo Peter Kang
This map shows the geographic impact of Soonmo Peter Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Soonmo Peter Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Soonmo Peter Kang more than expected).
Fields of papers citing papers by Soonmo Peter Kang
This network shows the impact of papers produced by Soonmo Peter Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Soonmo Peter Kang. The network helps show where Soonmo Peter Kang may publish in the future.
Co-authors
The 25 scholars most cited alongside Soonmo Peter Kang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade Hit paper breakdown → | 2017 | 5274 |
| 2 | Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Hit paper breakdown → | 2014 | 1540 |
| 3 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial Hit paper breakdown → | 2018 | 1056 |
| 4 | Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma Hit paper breakdown → | 2016 | 905 |
| 5 | Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer Hit paper breakdown → | 2020 | 872 |
| 6 | Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer Hit paper breakdown → | 2020 | 832 |
| 7 | Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors Hit paper breakdown → | 2015 | 672 |
| 8 | Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus Hit paper breakdown → | 2018 | 403 |
| 9 | 2018 | 250 | |
| 10 | 2015 | 193 | |
| 11 | 2015 | 165 | |
| 12 | 2015 | 127 | |
| 13 | 2014 | 78 | |
| 14 | 2016 | 78 | |
| 15 | Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. | 2007 | 66 |
| 16 | 2010 | 61 | |
| 17 | 2008 | 59 | |
| 18 | 2017 | 58 | |
| 19 | 2009 | 51 | |
| 20 | 2008 | 42 |
About Soonmo Peter Kang
Soonmo Peter Kang is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Immunology and Surgery, having authored 44 papers that have together received 13.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (17 papers), Gastric Cancer Management and Outcomes (5 papers), Pancreatic and Hepatic Oncology Research (5 papers), Esophageal Cancer Research and Treatment (5 papers), Cancer Genomics and Diagnostics (4 papers), CAR-T cell therapy research (4 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cancer Cells and Metastasis (3 papers). The work is most often cited by research in Oncology (8.1k citations), Immunology (2.7k citations), Cancer Research (1.6k citations), Pulmonary and Respiratory Medicine (2.7k citations) and Pathology and Forensic Medicine (1.5k citations). Soonmo Peter Kang has collaborated with scholars based in United States, Japan and South Korea. Frequent co-authors include Scot Ebbinghaus, Muhammad Wasif Saif, Mark J. Ratain, Anthony Michael Joshua, Leila Khoja, Marcus Otho Butler, Lyndsay N. Harris, Kapil Mayawala, Dinesh P. de Alwis and Jeffrey R. Sachs. Their work appears in journals such as Annals of Oncology, Clinical Cancer Research, Journal for ImmunoTherapy of Cancer, Journal of Clinical Oncology and JAMA Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.